Skip to main content
Top
Published in: Dysphagia 6/2019

01-12-2019 | Parkinson's Disease | Original Article

Dysphagia in Parkinson’s Disease Improves with Vocal Augmentation

Authors: R. J. Howell, H. Webster, E. Kissela, R. Gustin, F. Kaval, B. Klaben, S. Khosla

Published in: Dysphagia | Issue 6/2019

Login to get access

Abstract

While voice-related disorders in Parkinson’s disease (PD) are commonly discussed in the literature, dysphagia in PD is less widely published. Vocal fold augmentation, including injection laryngoplasty (IL), is a well-established treatment for glottal insufficiency (Cates et al. in Otolaryngol Head Neck Surg 155(3):454–457, 2016). This study aimed to observe the effects of IL in PD patients with vocal bowing, with or without therapy, on glottic closure and patient-reported dysphagia outcomes. The study design was based on retrospectively collected database and cohort–case series. PD patients selected for retrospective review over a 2-year period were referred and evaluated in the Voice, Swallowing, and Airway multidisciplinary clinic by speech language pathologist and laryngologist, and were undergoing IL. Charts were reviewed for age, gender, Body Mass Index (BMI), onset of PD, and Movement Disorders Society-Unified Parkinson’s Disease Rating Scale Part 3 (MDS-UPDRS) scoring. We compared pre/postoperatively (> 1 < 3 months) using validated patient-reported outcome tools: Reflux Symptom Index (RSI), Glottal Function Index (GFI), Eating Assessment Tool-10 (EAT), and stroboscopic examinations. The study included 14 patients undergoing 22 IL or 1.6 IL/patient: mean age 70 years (63–80), 100% male, and BMI 25.9 ± 4.3 (mean ± SD). MDS-UPDRS scoring 33 ± 20 (moderate severity), with time between PD diagnosis and IL 8 ± 10 years. All patients had pre- and post-stroboscopic examinations; however, only 4:14 underwent formal swallowing evaluation. Overall, 14 IL patients improved on patient-reported measures (ΔRSI = 4; ΔGFI = 3; ΔEAT = 4). Based on the findings of the study, we conclude that PD is a progressive neurodegenerative condition with dysphagia. The presented pilot data suggest that IL may be considered as a beneficial adjunct for PD patients with glottal insufficiency.

Level of Evidence

4.
Literature
1.
go back to reference Cates DJ, Venkatesan NN, Strong B, Kuhn MA, Belafsky PC. Effect of vocal fold medialization on dysphagia in patients with unilateral vocal fold immobility. Otolaryngol Head Neck Surg. 2016;155(3):454–7.CrossRef Cates DJ, Venkatesan NN, Strong B, Kuhn MA, Belafsky PC. Effect of vocal fold medialization on dysphagia in patients with unilateral vocal fold immobility. Otolaryngol Head Neck Surg. 2016;155(3):454–7.CrossRef
2.
go back to reference Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90.CrossRef Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90.CrossRef
3.
go back to reference Liu B, Chen H, Fang F, Tillander A, Wirdefeldt K. Early-life factors and risk of Parkinson’s disease: a register-based cohort study. PLoS ONE. 2016;11(4):e0152841.CrossRef Liu B, Chen H, Fang F, Tillander A, Wirdefeldt K. Early-life factors and risk of Parkinson’s disease: a register-based cohort study. PLoS ONE. 2016;11(4):e0152841.CrossRef
4.
go back to reference Ho AK, Iansek R, Marigliani C, Bradshaw JL, Gates S. Speech impairment in a large sample of patients with Parkinson’s disease. Behav Neurol. 1998;11(3):131–7.CrossRef Ho AK, Iansek R, Marigliani C, Bradshaw JL, Gates S. Speech impairment in a large sample of patients with Parkinson’s disease. Behav Neurol. 1998;11(3):131–7.CrossRef
5.
go back to reference Ramig LO, Sapir S, Countryman S, Pawlas AA, O’Brien C, Hoehn M, Thompson LL. Intensive voice treatment (LSVT) for patients with Parkinson’s disease: a 2 year follow-up. J Neurol Neurosurg Psychiatry. 2001;71(4):493–8.CrossRef Ramig LO, Sapir S, Countryman S, Pawlas AA, O’Brien C, Hoehn M, Thompson LL. Intensive voice treatment (LSVT) for patients with Parkinson’s disease: a 2 year follow-up. J Neurol Neurosurg Psychiatry. 2001;71(4):493–8.CrossRef
6.
go back to reference Beyer MK, Herlofson K, Arsland D, Larsen JP. Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand. 2001;103(1):7–11.CrossRef Beyer MK, Herlofson K, Arsland D, Larsen JP. Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand. 2001;103(1):7–11.CrossRef
7.
go back to reference D’Amelio M, Ragonese P, Morgante L, et al. Long-term survival of Parkinson’s disease: a population-based study. J Neurol. 2006;253(1):33–7.CrossRef D’Amelio M, Ragonese P, Morgante L, et al. Long-term survival of Parkinson’s disease: a population-based study. J Neurol. 2006;253(1):33–7.CrossRef
8.
go back to reference Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.CrossRef Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.CrossRef
9.
go back to reference Martinez-Martin P, Rodriguez-Blazquez C, Mario A, et al. Parkinson’s disease severity levels and MDS-unified Parkinson’s disease rating scale. Parkinsonism Relat Disord. 2015;21(1):50–4.CrossRef Martinez-Martin P, Rodriguez-Blazquez C, Mario A, et al. Parkinson’s disease severity levels and MDS-unified Parkinson’s disease rating scale. Parkinsonism Relat Disord. 2015;21(1):50–4.CrossRef
10.
go back to reference Bach KK, Belafsky PC, Wasylik K, Postma GN, Koufman JA. Validity and reliability of the Glottal Function Index. Arch Otolaryngol Head Neck Surg. 2005;131(11):961–4.CrossRef Bach KK, Belafsky PC, Wasylik K, Postma GN, Koufman JA. Validity and reliability of the Glottal Function Index. Arch Otolaryngol Head Neck Surg. 2005;131(11):961–4.CrossRef
11.
go back to reference Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux symptom index (RSI)). J Voice. 2002;16(2):274–7.CrossRef Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux symptom index (RSI)). J Voice. 2002;16(2):274–7.CrossRef
12.
go back to reference Belafsky PC, Mouadeb DA, Rees CJ, et al. Validity and reliability of the eating assessment tool (EAT-10). Ann Otol Rhinol Laryngol. 2008;117(12):919–24.CrossRef Belafsky PC, Mouadeb DA, Rees CJ, et al. Validity and reliability of the eating assessment tool (EAT-10). Ann Otol Rhinol Laryngol. 2008;117(12):919–24.CrossRef
13.
go back to reference Bové MJ, Jabbour N, Krishna P, Flaherty K, Saul M, Wunar R, Rosen CA. Operating room versus office-based injection laryngoplasty: a comparative analysis of reimbursement. Laryngoscope. 2007;117(2):226–30.CrossRef Bové MJ, Jabbour N, Krishna P, Flaherty K, Saul M, Wunar R, Rosen CA. Operating room versus office-based injection laryngoplasty: a comparative analysis of reimbursement. Laryngoscope. 2007;117(2):226–30.CrossRef
14.
go back to reference Roberts DP, Lewis SJG. Considerations for general anaesthesia in Parkinson’s disease. J Clin Neurosci. 2018;48:34–41.CrossRef Roberts DP, Lewis SJG. Considerations for general anaesthesia in Parkinson’s disease. J Clin Neurosci. 2018;48:34–41.CrossRef
15.
go back to reference Pepper PV, Goldstein MK. Posteroperative complications in Parkinson’s disease. J Am Geriatr Soc. 1999;47(8):967–72.CrossRef Pepper PV, Goldstein MK. Posteroperative complications in Parkinson’s disease. J Am Geriatr Soc. 1999;47(8):967–72.CrossRef
16.
go back to reference Berke GS, Gerratt B, Kreiman J, Jackson K. Treatment of Parkinson hypophonia with percutaneous collagen augmentation. Laryngoscope. 1999;109(8):1295–9.CrossRef Berke GS, Gerratt B, Kreiman J, Jackson K. Treatment of Parkinson hypophonia with percutaneous collagen augmentation. Laryngoscope. 1999;109(8):1295–9.CrossRef
17.
go back to reference Hill AN, Jankovic J, Vuong KD, Donovan D. Treatment of hypophonia with collagen vocal cord augmentation in patients with Parkinsonism. Mov Disord. 2003;18(10):1190–2.CrossRef Hill AN, Jankovic J, Vuong KD, Donovan D. Treatment of hypophonia with collagen vocal cord augmentation in patients with Parkinsonism. Mov Disord. 2003;18(10):1190–2.CrossRef
18.
go back to reference Remacle M, Lawson G. Results with collagen injection into the vocal folds for medialization. Curr Opin Otolaryngol Head Neck Surg. 2007;15(3):148–52.CrossRef Remacle M, Lawson G. Results with collagen injection into the vocal folds for medialization. Curr Opin Otolaryngol Head Neck Surg. 2007;15(3):148–52.CrossRef
21.
go back to reference Ruddy BH, Pitts TE, Lehman J, Spector B, Lewis V, Sapienza CM. Improved voluntary cough immediately following office-based vocal fold medialization injections. Laryngoscope. 2014;124(7):1645–7.CrossRef Ruddy BH, Pitts TE, Lehman J, Spector B, Lewis V, Sapienza CM. Improved voluntary cough immediately following office-based vocal fold medialization injections. Laryngoscope. 2014;124(7):1645–7.CrossRef
22.
go back to reference Silverman EP, Carnaby G, Singletary F, Hoffman-Ruddy B, Yeager J, Sapienza C. Measurement of voluntary cough production and airway protection in Parkinson disease. Arch Phys Med Rehabil. 2016;97(3):413–20.CrossRef Silverman EP, Carnaby G, Singletary F, Hoffman-Ruddy B, Yeager J, Sapienza C. Measurement of voluntary cough production and airway protection in Parkinson disease. Arch Phys Med Rehabil. 2016;97(3):413–20.CrossRef
Metadata
Title
Dysphagia in Parkinson’s Disease Improves with Vocal Augmentation
Authors
R. J. Howell
H. Webster
E. Kissela
R. Gustin
F. Kaval
B. Klaben
S. Khosla
Publication date
01-12-2019
Publisher
Springer US
Published in
Dysphagia / Issue 6/2019
Print ISSN: 0179-051X
Electronic ISSN: 1432-0460
DOI
https://doi.org/10.1007/s00455-019-09982-z

Other articles of this Issue 6/2019

Dysphagia 6/2019 Go to the issue